Cimetidine

CLINICAL USE

H2 antagonist:Conditions associated with hyperacidity Refractory uraemic pruritus (unlicensed use)

DOSE IN NORMAL RENAL FUNCTION

Oral: duodenal and gastric ulceration treatment: 800 mg at night, or 400 mg twice daily; rarely, up to 1.6 g dailyProphylaxis: 400 mg at night or 400 mg twice dailyProphylaxis of stress ulceration: 200– 400 mg every 4–6 hoursReflux oesophagitis: 400 mg every 6 hours IM/IV: 200 mg every 4–6 hours, maximum 2.4 g dailyIV Infusion: 200–400 mg every 4–6 hours intermittent or 50–100 mg/hour continuous, maximum 2.4 g dailyZollinger-Ellison syndrome: 400 mg every 4–6 hours

PHARMACOKINETICS

  • Molecular weight                           :252.3
  • %Protein binding                           :20
  • %Excreted unchanged in urine     : 50–75
  • Volume of distribution (L/kg)       :1–1.3
  • half-life – normal/ESRD (hrs)      :2–3/5

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : 50% of normal dose
  • <10           : 50% of normal dose

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Dose as in GFR <10 mL/min
  • HD                     :Dialysed. Dose as in GFR <10 mL/min
  • HDF/high flux   :Dialysed. Dose as in GFR <10 mL/min
  • CAV/VVHD      :Not dialysed. 300 mg every 8 hours1

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsAlpha-blockers: effects of tolazoline antagonisedAnti-arrhythmics: increased concentration of amiodarone, flecainide, lidocaine, procainamide and propafenoneAnticoagulants: enhanced effect of coumarinsAnti-epileptics: metabolism of carbamazepine, phenytoin and valproate inhibited. Antifungals: absorption of itraconazole and ketoconazole reduced; posaconazole concentration reduced; terbinafine concentration increasedAntimalarials: avoid concomitant use with artemether/lumefantrine; metabolism of chloroquine, hydroxychloroquine and quinine inhibitedAntipsychotics: possibly enhanced effect of antipsychotics, chlorpromazine and clozapine; increased risk of ventricular arrhythmias with sertindole – avoid concomitant useCiclosporin: possibly increased ciclosporin levelsCilostazol: possibly increased cilostazol concentration – avoid concomitant useCytotoxics: concentration of epirubicin and fluorouracil increased.156 CiMETidinEErgot alkaloids: increased risk of ergotism – avoid concomitant useTheophylline: metabolism of theophylline inhibited

    ADMINISTRATION

    Reconstition

    Route

    Oral, IM, IV

    Rate of Administration

    IV Infusion: 400 mg in 100 mL sodium chloride 0.9% or glucose 5% over 30–60 minutesIV bolus: 200 mg over at least 5 minutes. Dilute larger doses to 10 mL and give over at least 10 minutesContinuous IV Infusion: 50–100 mg/hour

    Comments

    Avoid bolus if possible

    OTHER INFORMATION

    Inhibits tubular secretion of creatinine Uraemic patients susceptible to mental confusion

  • Related News